***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: PURPOSE The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer . This international , double-blind , phase III study compared everolimus efficacy and safety with that of best supportive care ( BSC ) in previously treated advanced gastric cancer . PATIENTS AND METHODS Patients with advanced gastric cancer that progressed after one or two lines of systemic chemotherapy were r and omly assigned to everolimus 10 mg/d ( assignment schedule : 2:1 ) or matching placebo , both given with BSC . R and omization was stratified by previous chemotherapy lines ( one v two ) and region ( Asia v rest of the world [ ROW ] ) . Treatment continued until disease progression or intolerable toxicity . Primary end point was overall survival ( OS ) . Secondary end points included progression-free survival ( PFS ) , overall response rate , and safety . RESULTS Six hundred fifty-six patients ( median age , 62.0 years ; 73.6 % male ) were enrolled .  Median OS was 5.4 months with everolimus and 4.3 months with placebo ( hazard ratio , 0.90 ; 95 % CI , 0.75 to 1.08 ; P = .124 ) . Median PFS was 1.7 months and 1.4 months in the everolimus and placebo arms , respectively ( hazard ratio , 0.66 ; 95 % CI , 0.56 to 0.78 ) . Common grade 3/4 adverse events included anemia , decreased appetite , and fatigue . The safety profile was similar in patients enrolled in Asia versus ROW . CONCLUSION Compared with BSC , everolimus did not significantly improve overall survival for advanced gastric cancer that progressed after one or two lines of previous systemic chemotherapy . The safety profile observed for everolimus was consistent with that observed for everolimus in other cancers Purpose Fluoropyrimidine ( F ) and platinum ( P ) combination chemotherapy has been widely used as a first-line treatment of advanced gastric cancer ( AGC ) .  Docetaxel has shown promising activity against this disease . In this study , we explored the efficacy and safety of docetaxel monotherapy as salvage chemotherapy in AGC after F and P combination chemotherapy failed . Material s and methods From October 2004 to October 2005 , 49 eligible patients were enrolled in this study . The median treatment-free interval was 28.0 days , and 81.6 % of patients had suffered cancer progression within 4 months after the withdrawal of first-line chemotherapy . Docetaxel was given IV at a dose of 75 mg/m2 every 3 weeks , together with dexamethasone prophylaxis . Results A total of 182 cycles of docetaxel were administered with a median of 3 ( range 1–9 ) cycles . From an intention-to-treat analysis , eight patients achieved objective response with a response rate of 16.3 % ( 95 % CI , 6.0–26.6 ) . The median response duration was 4.7 months . A total of 20 patients showed stable disease , but 17 patients suffered disease progression . At a median follow-up duration of 11.3 months for surviving patients ( range 6.3–18.8 months ) , the median time to disease progression was 2.5 months ( 95 % CI , 2.3–2.7 ) and the median overall survival time since the start of docetaxel monotherapy was 8.3 months ( 95 % CI , 6.7–9.8 ) . Grade 3/4 neutropenia and febrile neutropenia occurred in 18.4 % of patients and in 5.4 % of cycles . The incidence of non-hematologic toxicities of grade 3 or worse was asthenia 32.7 % , diarrhea 10.2 % and peripheral sensory neuropathy 8.2 % . Conclusion Docetaxel at 75 mg/m2 is active against AGC as second-line chemotherapy after prior exposure to F and P combination chemotherapy . The toxicity profile is moderate PURPOSE When design ing this trial , there was no evidence that salvage chemotherapy ( SLC ) in advanced gastric cancer ( AGC ) result ed in substantial prolongation of survival when compared with best supportive care ( BSC ) . However , SLC is often offered to pretreated patients with AGC for anecdotal reasons . PATIENTS AND METHODS Patients with AGC with one or two prior chemotherapy regimens involving both fluoropyrimidines and platinum and with an Eastern Cooperative Oncology Group performance status ( PS ) 0 or 1 were r and omly assigned in a ratio of 2:1 to SLC plus BSC or BSC alone . Choice of SLC-either docetaxel 60 mg/m(2 ) every 3 weeks or irinotecan 150 mg/m(2 ) every 2 weeks-was left to the discretion of investigators . Primary end point was overall survival ( OS ) . RESULTS Median OS was 5.3 months among 133 patients in the SLC arm and 3.8 months among 69 patients in the BSC arm ( hazard ratio , 0.657 ; 95 % CI , 0.485 to 0.891 ; one-sided P = .007 ) . OS benefit for SLC was consistent in most of the prospect ively defined subgroups , including age , PS , number of prior treatments , metastatic sites , hemoglobin levels , and response to prior chemotherapy .  SLC was generally well tolerated , and adverse events were similar in the SLC and BSC arms . We found no median OS difference between docetaxel and irinotecan ( 5.2 v 6.5 months ; P = .116 ) . CONCLUSION To our knowledge , this is the largest phase III trial comparing SLC plus BSC with BSC alone in AGC . In pretreated patients , SLC is tolerated and significantly improves OS when added to BSC 
    Output:
    
More toxicities occurred in the TLT arms .